Filtered By:
Source: Heart Rhythm
Condition: Bleeding
This page shows you your search results in order of date.
Order by Relevance | Date
Total 42 results found since Jan 2013.
EP News Clinical
Kirchof and colleagues (N Engl J Med. 2003; epub Aug. 25: PMID: 37622677) conducted a, double-blind, double-dummy, randomized trial of patients> 65 years with device-detected atrial high-rate episodes (AHREs)> 6 minutes. Patients were randomized to edoxaban (E) or placebo (P). The primary efficacy outcome was a composite of cardiovascular death, stroke, or systemic embolism. The safety outcome was a composite of death from any cause or major bleeding. Overall, 2536 patients were randomized, including 1270 to E and 1266 to P.
Source: Heart Rhythm - September 7, 2023 Category: Cardiology Authors: N. A. Mark Estes Source Type: research
EP News: Clinical
Kirchof et al (N Engl J Med August 25, 2003; https://doi.org/10.1056/NEJMoa2303062, PMID 37622677) conducted a double-blind, double-dummy, randomized trial of patients 65 years and older with device-detected atrial high-rate episodes lasting for ≥6 minutes. Patients were randomized to edoxaban (E) or place bo (P). The primary efficacy outcome was a composite of cardiovascular death, stroke, or systemic embolism. The safety outcome was a composite of death from any cause or major bleeding. Overall, 2536 patients were randomized, including 1270 to E and 1266 to P.
Source: Heart Rhythm - September 7, 2023 Category: Cardiology Authors: N.A. Mark Estes Tags: EP NEWS Source Type: research
Po-01-167 efficacy of botulinum toxin type a (agn-151607) for the prevention of postoperative atrial fibrillation in cardiac surgery patients: atrial fibrillation and anticoagulation results from the phase 2 nova study
Oral anticoagulation reduces the risk of stroke but also increases the risk of bleeding. Prevention of post-operative atrial fibrillation (POAF) could result in a lower burden of oral anticoagulation and bleeding events. AGN-151607 has been proposed to prevent POAF and its safety/efficacy was tested in a multicenter randomized trial.
Source: Heart Rhythm - May 1, 2023 Category: Cardiology Authors: Nathan Waldron, Alexandra OSullivan, Jonathan P. Piccini, Matthew Romano, Pierre Voisine, Wilson Titanji, Richard Leaback, William Ferguson, Jonathan S. Steinberg Source Type: research
Po-01-140 atrial fibrillation and septic shock: a five-year retrospective observational study of anticoagulation usage, bleeding and stroke rates
Anticoagulation (AC) for atrial fibrillation (AF) is a cornerstone of management, and the benefit of mitigating stroke risk is accompanied by an increased risk of bleeding. The risk and benefit of AC in septic shock remains unclear as this disruptive hyperinflammatory state leads to multi-organ dysfunction, which can include coagulopathies.
Source: Heart Rhythm - May 1, 2023 Category: Cardiology Authors: Jonathan Na, Joanne Moon, Sahitya Allam, Maria Abraham, Kevin Chen, Ethan Kotloff, Yash Desai, Simin Hossain, Christopher Messner, Elnaz Esmati, Thomas Kutner, Gregory Norcross, James Childress, Paul Han, Ian Welch, Michael Sokolow, Libin Wang, Vincent Se Source Type: research
Po-03-190 safety and outcomes of left atrial appendage occlusion in nonagenarians
As the human lifespan continues to lengthen, so too will the incidence of atrial fibrillation and the need for anticoagulation for stroke prevention. However, many of these patients that require anticoagulation are also at high risk of bleeding making left atrial appendage occlusion (LAAO) an attractive option. Studies on the procedural risks in the very elderly are limited and the safety of LAAO in nonagenarians is lacking.
Source: Heart Rhythm - May 1, 2023 Category: Cardiology Authors: Anis John Kadado, Alexandra Marenco, Jishu Motta, Khalid Sawalha, Kyle Gobeil, Michel Farah, Guy Rozen, Marshal Fox, Fadi M. Chalhoub Source Type: research
Po-685-06 liver cirrhosis is associated with an increase in bleeding and mortality in patients undergoing left atrial appendage occlusion: insights from a nationwide cohort analysis
Patients with liver cirrhosis are at an increased risk of bleeding secondary to diminished clotting factor synthesis. In patients with both atrial fibrillation (AF) and cirrhosis, there is an additional risk of cardioembolic stroke. Thus, left atrial appendage occlusion (LAAO) is an attractive therapeutic option. There is limited data available that examine the safety and outcomes of LAAO in patients with cirrhosis.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Sahith Reddy Thotamgari, Aakash Sheth, Samarthkumar Thakkar, Harsh P. Patel, Abhishek J. Deshmukh, Christopher V. DeSimone Source Type: research
Po-684-02 lower rate of major bleeding in high-risk patients undergoing left atrial appendage occlusion: a propensity matched comparison with direct oral anticoagulation
Stroke prophylaxis in very high risk (CHA2DS2-VASc ≥ 5) patients with atrial fibrillation (AF) is one of the major challenges faced by physicians. Specifically, initiating direct oral anticoagulants (DOACs) in these patients poses a therapeutic conundrum due to the concomitant high risk of bleeding. Left atrial appendage occlusion (LAAO) might be a potential alternative for thromboembolic (TE) prevention; however, there are no studies comparing these two strategies in very high-risk patients.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Michele Magnocavallo, Domenico G. Della Rocca, Marco Schiavone, Marco Valerio Mariani, Giampaolo Vetta, Carola Gianni, Sanghamitra Mohanty, Mohamed A. Bassiouny, Carlo Lavalle, Giovanni FORLEO, J. David Burkhardt, Amin Al-Ahmad, G. Joseph Gallinghouse, Ro Source Type: research
Po-701-04 outcomes of left atrial appendage closure in patients with atrial fibrillation and end-stage renal disease on dialysis
Oral anticoagulation (OAC) therapy is the mainstay of treatment for stroke-risk reduction in patients with atrial fibrillation (AF). However, OAC use in patients with end-stage renal disease (ESRD) on dialysis is associated with a significantly increased risk of bleeding and an uncertain benefit in stroke reduction. In these patients, left atrial appendage closure (LAAC) could be alternative.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Jorge Romero, Juan C. Diaz, Sutopa Purkayastha, Jorge Marin, Julian M. Aristizabal, Daniel Rodriguez, Isabella Alviz, Mauricio Duque, Mohamed Gabr, Maria Gamero, Jose Matias, Marta Lorente-Ros, Luis Ernesto Cerna, Dhanunjaya R. Lakkireddy, Rishi Charate, Source Type: research
Hp-574-03 new-onset bleeding and subsequent risk of cardiovascular outcomes in anticoagulated patients with atrial fibrillation
The use of oral anticoagulation for stroke prevention in patients with atrial fibrillation (AF) increases their risk of bleeding. The prognosis of AF patients who experience a bleeding event is not well studied.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Pascal Meyre, Rebecca E. Paladini, Elisa Hennings, Stefanie Aeschbacher, Tobias Reichlin, Nicolas Rodondi, Annina Stauber, Andreas M üller, Giorgio Moschovitis, Giulio Conte, Angelo Auricchio, Matthias Schwenkglenks, Michael Kühne, Stefan Osswald, David Source Type: research
Po-670-07 optimising antithrombotic agents in patients undergoing left atrial appendage occlusion
Anticoagulants and/or antiplatelet agents are used in the perioperative period for left atrial appendage occluder (LAAO) implantation to reduce the risk of stroke related to atrial fibrillation (AF) or thrombus from the device. However, the indication for LAAO is often a bleeding condition that may be exacerbated by these drugs.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Balrik Kailey, Michael Koa-Wing, Norman A. Qureshi, Syed M. Sohaib, Christine Shi, Pritpal Padam, James Howard, Prapa Kanagaratnam Source Type: research
Po-717-05 prophylactic and preventive radiofrequency septal ablation to reduce the possibility of left ventricular outflow tract obstruction post-mitral valve replacement
The patients who have severe mitral annulus calcification leading severe mitral stenosis often are eldery and have comorbidities which increase surgical risk of stroke, embolization, and bleeding complications.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Natchayathipk Kittichamroen, Atul Verma Source Type: research
Ce-539-02 utilization of oral anticoagulation after bleeding events in stroke patients with atrial fibrillation
Oral anticoagulation (OAC) is recommended for stroke prophylaxis after diagnosis of atrial fibrillation (AF). However, the optimal strategy or timing for continuing OAC use after bleeding events in these patients has not been well established.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Paul Ziegler, shadi yaghi, Candace Gunnarsson, Michael Ryan, Sarah Rosemas, Matthew R. Reynolds Source Type: research
Po-716-08 real world clinical outcomes of left atrial appendage occlusion device in the octogenarian and nonagenarian patients
Few trials evaluated real world clinical outcomes in patients with atrial fibrillation receiving the Watchman device for left atrial appendage closure. In the recent Ewolution trial, mean age of patients was 73.4 + 8 years. Although few patients> 80 years were included, the safety and efficacy in terms of clinical outcomes of stroke, bleeding and mortality in the octogenarian and nonagenarian population specifically has not been reported in real world setting.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Javier Amione Guerra, Justin Haloot, Ahmed Almomani, David N. Pederson, Jayasree Pillarisetti Source Type: research
Liver cirrhosis is independently associated with increased in-hospital mortality in patients undergoing left atrial appendage occlusion device implantation
This study aimed to assess procedural outcomes in patients with cirrhosis who underwent LAAO with a Watchman device by using a contemporary administrative claims database.
Source: Heart Rhythm - April 28, 2022 Category: Cardiology Authors: Sahith Reddy Thotamgari, Aakash R. Sheth, Harsh P. Patel, John Bretzman, Robert C. Ward, Samarthkumar Thakkar, Jaimin T. Patel, Samuel J. Asirvatham, David R. Holmes, Alexander Egbe, Abhishek Deshmukh, Christopher V. DeSimone Tags: Research Letter Source Type: research
EP News: Allied Professionals
In this non-prespecified, post hoc analysis of the AUGUSTUS (The Open-Label, 2 x 2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention) trial (Harskamp et al. J Am Coll Cardiol. 2022;79:417-27. PMID-35115097), the authors sought to evaluate whether the risk of bleeding or stroke as assessed by baseline HAS-BLED and CHA2DS2-VASc scores affected the results of the trial.
Source: Heart Rhythm - March 9, 2022 Category: Cardiology Authors: Erica S. Zado Source Type: research
